- Home
- MNOV vs VTGN Comparison
MNOV vs VTGN Comparison
Compare MNOV & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | VTGN |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 28.8M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNOV | VTGN |
|---|---|---|
| Price | $1.31 | $0.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.00 | $0.90 |
| AVG Volume (30 Days) | 79.4K | ★ 6.1M |
| Earning Date | 02-18-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $257,917.00 | ★ $721,000.00 |
| Revenue This Year | N/A | $54.26 |
| Revenue Next Year | N/A | $478.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $0.63 |
| 52 Week High | $2.20 | $5.14 |
Technical Indicators
Market Signals| Indicator | MNOV | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 23.12 |
| Support Level | $1.25 | $0.63 |
| Resistance Level | $1.34 | $0.71 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 24.67 | 1.08 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.